The Latest Breaking News from DGX

Despite Quest Diagnostics’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

With Quest Diagnostics gearing up to release its third-quarter earnings later this month, analysts expect a low single-digit earnings growth.

Quest Diagnostics has outperformed the broader healthcare sector recently, and analysts are bullish about the stock's future.

As Quest Diagnostics underperformed relative to the S&P 500 Index over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

As Quest Diagnostics gears up to unveil its second-quarter earnings results, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Nvidia announced that its Grace Hopper CPU+GPU Superchips are now in production, and also introduced the DGX GH200 supercomputer and MGX platforms that will use its new AI-optimized Ethernet Spectrum-X networking platform.

Increasing cases of monkeypox worldwide have led the WHO to declare it a global emergency. With the infection spread in more than 85 countries and governments rushing to curb the spread, vaccine manufacturers are poised to benefit significantly. Thus, we think monkeypox stocks Quest Diagnostics (DGX) and SIGA Technologies (SIGA)…

Quest Diagnostics Inc (NYSE:DGX) posted a better-than-expected Q1 FY22 adjusted EPS of $3.22, down 14.4% Y/Y, beating the consensus of $2.97. Sales came in at $2.61 billion, a decline of 4% Y/Y, slightly lower than the Wall Street estimate of $2.63 billion. COVID-19 testing revenues fell 27.6% to $599 million, while Base…

The Centers for Disease Control and Prevention (CDC) has granted a contract to Quest Diagnostics Inc (NYSE:DGX) to perform testing and provide laboratory data analysis to help identify patterns in SARS-COV-2 seroprevalence on a multistate basis.  Quest was awarded the contract following a competitive bid. The total contract value with all options is valued…

If history is any guide, there may be trouble ahead for shares of Quest Diagnostics (NYSE:DGX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

The healthcare industry is expected to achieve solid growth with rising investments in the sector and soaring demand from an aging population. Therefore, we think it could be wise to bet on beaten-down healthcare stocks West Pharmaceutical (WST), Bio-Rad Laboratories (BIO), Quest Diagnostics (DGX), and Masimo Corporation (MASI), which possess…